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Summary The aim of this study was to test the effectiveness of a regimen ofcombination chemotherapy when
given as an adjuvant treatment after mastectomy to patients with histologically negative axillary lymph nodes.
A total of 574 patients with cancer of the breast and no involvement of axillary lymph nodes were
randomised, after simple mastectomy with axillary sampling, to receive either no adjuvant treatment or oral
fluorouracil 500 mg, methotrexate 25 mg and chlorambucil 10 mg p.o. on day 1 and fluorouracil 500 mg and
chlorambucil 10mg p.o. on day 2 (LMF) every 21 days for eight cycles. Randomisation was stratified
according to menopausal status and tumour size. Treatment was started within 14 days of surgery in 97% of
patients. Ninety per cent of patients received eight cycles of chemotherapy with no dose reduction. At a
median follow-up of 7 years, there was no evidence that relapse-free or overall survival time were influenced by
treatment.
Although patients with node negative breast cancer are
thought to have a good prognosis, approximately 25% will
have relapsed 5 years after primary treatment (Friedman et
al., 1986). It is clear from extensive clinical experience that
relapse is almost always associated with subsequent death
from breast cancer. Thus, if approximately one-quarter of
patients with node negative breast cancer die of their disease,
this is only a good prognosis in relation to node positive
disease; it is a poor prognosis in relation to no disease.
Patients with node negative disease who relapse do so on
average later than those with node positive disease (Nissen-
Meyer et al., 1986). This suggests that at presentation they
have a smaller tumour burden. Since experimental data
indicate that adjuvant chemotherapy is more active the
smaller the tumour burden, these patients should
theoretically benefit from treatment more than those with
node positive disease.
We therefore decided to test the hypothesis that patients
with node negative disease would benefit from chemotherapy
by using oral chlorambucil, methotrexate and fluorouracil
(LMF). Treatment was to begin as soon as possible after
mastectomy in view of the Nissen-Meyer study which showed
an advantage for early treatment (Nissen-Meyer et al., 1986).
The trial was started in December 1976 as a multicentre
study within the West Midlands region of the United King-
dom. Preliminary analyses of the study were reported when
the median follow-up times were 22, 54 and 60 months
(Morrison et al., 1981, 1984, 1987). This paper presents a
more complete analysis of the trial 10 years after recruitment
began when the median follow-up was 7 years.
Patients and methods
Selection ofpatients
Patients were entered into the trial by 40 consultant surgeons
from 26 hospitals within the West Midlands Region between
December 1976 and August 1984. Patients without axillary
lymph node involvement, TIa-T3a tumours and below the age
of 65 were eligible. Additional eligibility criteria were: WBC
>4.0 x 1091- 1', platelet count > 100 x 1091-', normal liver
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function tests, not pregnant or lactating, no previous malig-
nancy except rodent ulcer, squamous cell carcinoma of skin
or carcinoma in situ of cervix, no serious intercurrent disease
or psychiatric disorder and ability to be followed up ade-
quately. Mandatory initial investigations were full blood
count, biochemical profile, liver function tests, ECG, chest
and skeletal radiographs and a radioisotope bone scan.
Treatment
Following histological confirmation of the diagnosis all
patients had a simple mastectomy with axillary node samp-
ling (Forrest et al., 1976). Postoperative radiotherapy was not
given. After confirmation of axillary node status, patients
were randomised by telephone call to the West Midlands
Cancer Registry and after September 1983 to the West Mid-
lands Cancer Research Campaign Clinical Trials Unit to
receive either no further treatment or chemotherapy. Pro-
spective stratification was made for menopausal status and
tumour size (<5 cm; > 5 cm). Chemotherapy was started
within 7 days of surgery in 81% of patients and 14 days in
97%. A further seven cycles were given every 21 days on an
outpatient basis. Patients received orally fluorouracil 500 mg,
methotrexate 25 mg and chlorambucil 10mg on day 1. On
day 2 they received orally fluorouracil 500 mg and chloram-
bucil 10mg. Courses were delayed if there was evidence of
significant myelosuppression (WBC <3 x 1091-1; platelets
< 100 X 109 1-') or other serious toxic manifestations. There
were no dosage reductions. Treatment after relapse was
decided by clinicians individually.
Assessment
Patients were examined every 3 months for 18 months and
thereafter at 6-monthly intervals until recurrence or death. A
full blood count, biochemical profile and liver function tests
were performed at each visit. Chest and skeletal X-rays and
bone scans were performed 6-monthly for 2 years followed
by annual investigations until 5 years. Toxicity was recorded
for each treatment cycle. Nausea and vomiting were graded
as mild or severe on a subjective basis by each surgical team.
Clinicians were also asked to report the duration of major
symptoms in days.
Pathology and receptors
Histology was reviewed centrally by one of us (R.A.W.) and
classified according to histological type and grade; the
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grading used (Elston et al., 1982) was a modification of the
system used by Bloom and Richardson (1957). Oestrogen and
progesterone receptors were assayed using the dextran coated
charcoal method and Scatchard analysis (McGuire & De La
Garza, 1973). Receptors were taken to be present if > 5 fmol
per mg cytosol protein were detectable.
Audit
All recurrences were verified histologically if superficial, or by
radiology and scanning if not, and reviewed by one of us
(J.M.M.). External audit was performed by Dr T.J. Powles in
November 1985. Computer files, trial forms, clinical notes
and X-rays were examined for every twentieth patient and
for a random sample of patients with recurrence in the bone
and lung.
Statistical analyses
The major end-points of the trial were histologically or
radiologically defined recurrence and death. The com-
pleteness of the notification of death was verified by registra-
tion of all patients with the West Midlands Regional Cancer
Registry, Birmingham, and the National Health Service Cen-
tral Register, Southport. In accordance with accepted statis-
tical practice, this permitted all randomised patients to be
included in the survival analysis (Peto et al., 1977). However,
since there was no notification by clinicians of disease status
for patients who were randomised but were found subse-
quently to be ineligible, only eligible patients are included in
the analysis of recurrence, relapse-free survival and toxicity.
Relapse-free survival and overall survival curves were drawn
using the method of Kaplan and Meier (1958) and the
significance of the differences between curves assessed using
the log rank test (Peto et al., 1977). Treatment comparisons
were stratified by menopausal status and tumour size. In
addition the effect of controlling for menopausal status,
tumour size, age, tumour grade and receptor content was
determined using Cox's multiple regression analysis (Cox,
1972). The reduction in the odds of relapse and death (Early
Breast Cancer Trialists' Collaborative Group, 1988) and
relative improvements were calculated. Patients with uncer-
tain menopausal status (e.g. previous hysterectomy) were
taken to be premenopausal if less than 50 years and post-
menopausal if 50 years or more. Patients were taken to be
post-menopausal if they had had no periods within the
previous 6 months.
Results
Patients analysed
A total of 574 patients were randomised (285 treated and 289
control) of whom 543 (273 treated and 270 control) were
eligible according to the criteria given above. Data were
censored at 31 December 1986 when the median follow-up
was 7 years. Analysis of survival includes all randomised
patients whereas other analyses were performed on eligible
patients only; the 31 ineligible patients (13 treated and 18
control) were not followed up. Patients were excluded after
randomisation for the following reasons: nodes not sampled
or node positive (four treated, five control); advanced disease
(two treated); too old (two treated, five control); white blood
count too low (one control); abnormal LFTs (two treated,
four control); other malignancy (one treated, two control);
carcinoma in situ (one treated); benign lump (one control);
intercurrent disease (one treated). One treated patient was
completely lost to follow-up and is not included in the
analysis of recurrence. The characteristics of the eligible
patients are given in Table I, which shows that there are no
major imbalances of prognostic factors between the treated
and control groups.
Relapse-free survival
Adjuvant chemotherapy had no significant effect on relapse-
free survival (Figure 1, Table II). The percentage relapse-free
at 5 years is 73% (95% confidence interval (CI) 67-78%) in
the treated and 71% (CI 65-76%) in the control group,
which represents a relative improvement (RI) of 3% in the
relapse rate at 5 years or an 11% reduction in the odds of
relapse (OR). After stratification for menopausal status and
tumour size, the X2, is 0.51 (P = 0.47). Controlling for
menopausal status, tumour size, age, grade and receptor
status does not alter the result. For comparability with other
Table I Patient characteristics
Treated (273 patients)
n %
Age
Less than 50
50 plus
Menopausal status
Premenopausal
Post-menopausal
Hysterectomy
Tumour size
<2.0
2.0-4.9
>5.0
Histology
Infiltrating duct
Infiltrating lobular
Other
Not reviewed
Grade
I
III
Not reviewed
Oestrogen receptors
Negative
Positive
Not assayed
Progresterone receptors
Negative
Positive
Not assayed
119
154
129
116
28
51
184
38
199
27
27
20
38
144
71
20
61
121
91
67
82
124
44
56
48
42
10
19
67
14
73
10
10
7
14
53
26
7
22
44
33
25
30
45
Control (270 patients)
n %
127 47
143 53
128 47
120 45
22 8
64
180
26
194
38
22
16
44
153
54
19
51
124
95
75
74
121
24
67
9
72
14
8
6
16
57
20
7
19
46
35
28
27
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AVCMF 272 254 239 215 196 157 128 98 71 71 71
Control 270 243 227 214 186 151 125 67 67 28 28
Figure 1 Relapse-free interval for all eligible patients. LMF
(81/272 relapsed); control (88/270 relapsed); X2, = 0.58; P = 0.45.
studies, the results are broken down by menopausal status
and age in Table II. Since there was no effect of
chemotherapy overall, further subgroup analyses are not
presented.
There were 81 (30%) patients who recurred in the treated
group and 88 (33%) in the control group. Although the total
number of recurrences is similar in both groups, there was a
highly significant difference in the distribution of metastases
between the treated and control groups (x2, = 8.5;
P = 0.0004), 65% having distant recurrence in the treated
group and only 43% in the control group (Table III). An
equal number of local recurrences is expected in the treated
and control groups, but there were significantly more local
recurrences in the control group than expected on the basis
of a 1:1 ratio (X2, = 6.5; 0.02> P >0.01). However,
although there was a greater number of distant recurrences
than expected in the treated group, the deviation from a 1:1
ratio was not significant (X2I = 2.4; 0.2>P >0.1).
Table III Sites of first recurrence
Treated (81) Control (88)
n (%') n (%')
Local and regional recurrence only 28 (35) 50 (57)
Total with distant recurrence 52 (65) 37 (43)
Breakdown of distant recurrences
Bone 20 (25) 23 (26)
Liver 2 (2) 1 (1)
Lung 15 (19) 5 (6)
Otherb 12 (15) 4 (5)
Distant and local recurrence 3 (4) 4 (5)
Not reviewedc 1 1
a% of those reviewed. bAscites (3T), brain (IT,1C), contralateral
breast (8T,1C), contralateral axilla (2C). cDied with disease, but no
recurrence recorded.
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Figure 2 Survival for all randomised patients. LMF (56/285
died); control (56/289 died); X2, = 0.02; P = 0.88.
Survival
There was no significant effect of chemotherapy on overall
survival (Figure 2). After stratification for menopausal status
and tumour size, x21 = 0.11; P = 0.74. Controlling for
menopausal status, tumour size, age, tumour grade and
receptor status does not alter this result. The results overall
and broken down by menopausal status and tumour size are
shown in Table II.
Chemotherapy
Ninety percent of patients received eight cycles of treatment,
93% seven cycles or more and 96% four cycles or more; all
patients received at least two cycles of chemotherapy. The
reasons for not receiving the full course of eight cycles of
chemotherapy were toxicity (15%), intercurrent illness not
associated with treatment (3%), patient refusal (30%) and
administrative errors mainly involving failure to give the
eighth cycle (52%).
Toxicity
The proportion of patients affected and the number of cycles
in which toxic effects were seen in summarised in Table IV.
Severe leukopenia and thrombocytopenia were rare. Most
patients had nausea and vomiting on at least one occasion.
When these symptoms were analysed on a per cycle basis,
69% of cycles were associated with nausea and 32% with
vomiting. Treatment was delayed by one week in 74 cycles
and longer in 39. Mild alopecia occurred in a third of
patients, while other side-effects such as stomatitis or
neuropathy were uncommon.
The severity and duration of nausea and vomiting are
outlined in Figure 3. Severe symptoms were uncommon.
However, when symptoms occurred, they lasted for longer
than 24 hours in approximately a third of the cycles assessed.
An assessment of the 'quality of life' of patients is shown
in Figure 3. Patients were asked how long they were unwell,
how long they were unable to go to work (or perform
housework) and how long they were confined to bed if they
Table II Effect of treatment in subgroups of patients
Relapse-free survival Overall survival
Treated Control Treated Control
N R N R x2 p RI OR N D N D x21 p RI OR
Overall 272 81 270 88 0.58 0.45 3 11 285 56 289 56 0.02 0.88 0 -3
Menopausal status
Pre 137 38 134 47 1.51 0.22 6 23 143 27 139 28 0.07 0.79 -3 7
Post 135 43 136 41 0.02 0.89 0 -3 140 29 150 28 0.23 0.63 1 - 14
Age
<50 118 36 127 42 0.19 0.67 2 9 122 25 131 27 0.00 0.96 -2 1
>50 154 45 143 46 0.36 0.55 4 12 163 31 158 29 0.07 0.79 1 -7
N, number ofpatients in subgroup; R, number ofpatients who have relapsed; D, number ofpatients who have died; RI, relative improvement;
OR, odds reduction.
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Table IV Toxicity attributed to chemotherapy
Patients Cycles
Haematology
n (259) % n (1746) %
Hb (gdl-')
9.5- 10.9 26 10 57 5
<9.5 4 2 4 <1
WBCcount(x 191I-')
3-3.9 88 34 280 30
2-2.9 5 2 5 <1
<2 0 0 1 <1
Platelets (x 109l-')
70-99 4 2 1 -0
<70 2 1 2 -0
Side-effects
n (259) % n (1877) %
Nausea 243 94 1300 69
Vomiting 184 71 606 32
Rash 40 15 55 3
Stomatitis 62 24 110 6
Diarrhoea 66 25 133 7
Neurological 62 24 112 6
Mild hair loss 88 34
Cardiac failure 0 0
had toxicity. Patients were unwell in 57% of cycles. In 30%
of cycles patients took time off work and in 19% they were
confined to bed for a variable period.
Secondprimary tumours
Second primary tumours occurred in three of the controls
(colon, multiple myeloma, ovary) and three of the treated
group (colon, lung, pancreas). No leukaemias have been
recorded.
Discussion
After a median follow-up of 7 years, patients treated with
oral LMF did not have a relapse-free or overall survival
advantage compared with untreated controls. Although the
regimen of chemotherapy was designed to be non-toxic, it
proved to have much more toxicity than anticipated from
pilot studies. Indeed, the toxicity of this regimen appears
similar to the intravenous chemotherapy described in the
previous paper, with the exception of alopecia. It may be
more myelotoxic than AVCMF in susceptible patients since
the WBC immediately before the subsequent course was
between 3.0 and 3.9 x 1091` in 30% of LMF cycles and
14% of only AVCMF cycles. However, in spite of showing
activity in terms of myelosuppression, there was no detec-
table anti-tumour effect in terms of relapse-free or overall
survival.
The sites of first recurrence in this study were paradoxical.
Although the total number of recurrences was very similar,
there were significantly fewer local and regional recurrences
in treated patients (28 in the treated group and 50 in the
controls; X2I = 6.5; 0.2>P >0.01) whereas there were rather
more distant recurrences in treated patients (52 vs 37;
X21 = 2.4; 0.2> P >0.1), with the excess attributable to
recurrences in lung, contralateral breast and ascites. Explana-
tions for this effect must be conjectural and include chance,
immunosuppression or chemotherapy induced sublethal cell
damage leading to genetic alteration and subsequent in-
creased growth rates. This paradoxical phenomenon has not
led to a significantly worse survival in the treated arm.
The results of other trials comparing the use of prolonged
combination chemotherapy with a no treatment control arm
in node negative patients are shown in Table V (Koyama et
al., 1980; Senn et al., 1986; Semiglazov et al., 1986; Jakesz et
al., 1987; Ludwig Breast Cancer Study Group, 1989; Espie et
al., 1987; Bonadonna et al., 1987; Williams et al., 1987;
Mansour et al., 1989; Fisher et al., 1989). In most, low dose
oral or intravenous treatments have been studied in node
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Figure 3 Side-effects of treatment: nausea and vomiting and aspects of quality of life.
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Table V Randomised trials of adjuvant polychemotherapy compared with untreated controls in node negative patients
Period of Effect on relapse Effect on survival Median Date of
Author (study) accruaP nb Regimen' P valued % RF' P value' % alivee follow-up report
Trials with unselected node negative patients
Koyama (Japanese) 62-76 229 C and/or Mmc NS 94/90 (5) NS - -9 years 80
Senn (OSAKO) 74-77 122 LMF S _ NS - 9 years 86
Semiglazov (USSR) 75-82 252 CMF/TMF <0.05 90/81 (5) <0.10 87/80 (5) ~-6 years 86
Morrison (WMOA) 76-84 574 LMF 0.45 77/74 (4) 0.88 91/90 (4) 7 years 89
Jakesz (Viennese) 77-81 128 CMFVb - - <0.02 90/76 (0) 6 years 87
Ludwig (Swiss) 81-85 1275 CMF 0.04 77/73 (4) 0.24 90/86 (4) 3.5 years 89
Espie (Paris) - 165 CMF NS 59/53 (6) NS 82/92 (6) 3 years 87
Trials with ER negative node negative patients
Bonadonna (Milan) 80-85 90 CMF <0.001 89/53 (4) 0.02 93/63 (4) -3 years 87
Williams (Southampton) 81-85 52 VAP 0.001 95/68 (0) - 95/87 (0) 3 years 87
Mansour (ECOG) 81-88 406 CMFP 0.0001 84/69 (3) NS - 3 years 89
Fisher (NSAPB) 81- 679 MF 0.003 80/71 (4) 0.8 86/87 (4) 4 years 89
aAnalysis may be based on a shorter period for which there is adequate follow-up. bAnalysis based on this number ofpatients, more may have been
randomised. CC, cyclophosphamide; Mmc, mitomycin C; L, chlorambucil; M, methotrexate; F, fluorouracil; T, thiotepa; Vb, vinblastine; A,
adriamycin; P,prednisone. dNS, P>0.05; S, P <0.05; Pforlogrank testexcept ttestforSemiglazov. e% intreatedgroup/% incontrolgroup(yearat
which percentages given). 0, over the observation period; Semiglazov gives distant relapses only.
negative patients irrespective of receptor status. With the
exception of the Viennese study (Jakesz, 1987), there have
been no reported improvements in survival in this type of
study, which is not surprising in view of the small absolute
improvement possible in this good prognosis group and the
small sample sizes. Several studies report marginal im-
provements in relapse free survival (Senn et al., 1986; Semi-
glazov et al., 1986; Ludwig Breast Cancer Study Group,
1989). There is no significant improvement in either relapse-
free or overall survival in our trial. This could be due to the
chemotherapy used. In the overview of the Early Breast
Cancer Trialists' Collaborative Group (1988) CMF-based
regimens gave greater reductions in odds than regimens with-
out all or some of C, M, F and single agents, although there
was no significant heterogeneity between types of regimen.
However, Senn et al. (1986) report significantly improved
relapse-free survival with LMF and our failure to demon-
strate any significant benefit could be due to chance and the
relatively small number of patients studied for the magnitude
of improvement that now seems likely in this group.
These trials in unselected node negative patients are con-
founded not only by the relatively small numbers of patients
but also by the relatively low number and late occurrence of
events in node negative patients. More recent trials have tried
to select high risk groups on the basis of oestrogen receptor
status. These studies have all demonstrated highly significant
improvements in relapse free survival. In the NSAPB study
(Fisher et al., 1989), 741 node negative, ER negative patients
were randomised to receive methotrexate 100 mg m-2 i.v.
days 1 and 8 every 4 weeks and fluorouracil 600 mg m-2 i.v.
days 1 and 8 one hour after methotrexate for a period of 12
months or no further treatment. At 4 years there was a 9%
reduction in the absolute number of recurrences in the
chemotherapy treated group (relapse-free survival 80% vs
71%). ECOG (Mansour et al., 1989) randomised 536 node
negative, ER negative patients to receive cyclophosphamide
100 mg m and prednisone 40 mg m 2 orally days 1-14
with methotrexate 40 mg m-2 i.v. and fluorouracil
600 mgm-2 i.v. days 1 and 8, repeated 4-weekly. At 3 years
there was a highly significant improvement in relapse-free
survival (84% vs 69%). Bonadonna et al. (1987) randomised
90 node negative, ER negative patients to receive cyclophos-
phamide 600 mgm-2, fluorouracil 600 mgm-2 and
methotrexate 40 mg m-2 i.v. every 21 days for 12 cycles. At 3
years there was a significant improvement in relapse-free
survival (89% vs 53%) and overall survival (93% vs 63%).
Although there was no heterogeneity between types of
regimen in the overview, it may well be that less intensive
regimens do not provide adequate treatment. If the NSAPB,
ECOG and Milan results are meaningful, it might suggest
that if node negative patients are treated with adjuvant
chemotherapy, high risk groups should be selected and
regimens shown to be active in node positive disease used in
full doses.
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